PMID: 19944015Dec 1, 2009Paper

The novel peptide F29 facilitates the DNA-binding ability of hypoxia-inducible factor-1alpha

BMB Reports
Su Mi Choi, Hyunsung Park

Abstract

Hypoxia-inducible factor-1alpha/beta (HIF-1alpha/beta) is a heterodimeric transcriptional activator that mediates gene expression in response to hypoxia. HIF-1alpha has been noted as an effective therapeutic target for ischemic diseases such as myocardiac infarction, stroke and cancer. By using a yeast two-hybrid system and a random peptide library, we found a 16-mer peptide named F29 that directly interacts with the bHLH-PAS domain of HIF-1alpha. We found that F29 facilitates the interaction of the HIF-1alpha/beta heterodimer with its target DNA sequence, hypoxia-responsive element (HRE). The transient transfection of an F29-expressing plasmid increases the expression of both an HRE-driven luciferase gene and the endogenous HIF-1 target gene, vascular endothelial growth factor (VEGF). Taken together, we conclude that F29 increases the DNA-binding ability of HIF-1alpha, leading to increased expression of its target gene VEGF. Our results suggest that F29 can be a lead compound that directly targets HIF-1alpha and increases its activity.

References

Jun 6, 1995·Proceedings of the National Academy of Sciences of the United States of America·G L WangG L Semenza
Aug 23, 2001·Trends in Molecular Medicine·G L Semenza
Oct 13, 2001·Science·R K Bruick, S L McKnight
Sep 27, 2002·Current Opinion in Pharmacology·Mark A Lindsay
Jun 28, 2003·Journal of Cell Science·Norma Masson, Peter J Ratcliffe
Jul 24, 2003·The Journal of Biological Chemistry·Sujin YimHyunsung Park
Sep 18, 2003·Nature Reviews. Cancer·Gregg L Semenza
Apr 23, 2008·Molecular Pharmacology·Hyunju ChoEun Gyeong Yang

❮ Previous
Next ❯

Citations

Apr 17, 2010·Molecules and Cells·Agnieszka LobodaJozef Dulak

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.